FDA — authorised 17 April 2018
- Application: BLA761068
- Marketing authorisation holder: KYOWA KIRIN
- Indication: Type 1 - New Molecular Entity
- Status: approved
🇺🇸 Crysvita in United States
FDA authorised Crysvita on 17 April 2018
Marketing authorisation
Crysvita in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Rare Disease approved in United States
Frequently asked questions
Is Crysvita approved in United States?
Yes. FDA authorised it on 17 April 2018.
Who is the marketing authorisation holder for Crysvita in United States?
KYOWA KIRIN holds the US marketing authorisation.